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Abstract Human positive transcription elongation factor b (P-TEFb) phosphorylates RNA 
polymerase II and regulatory proteins to trigger elongation of many gene transcripts. The HIV-1 Tat 
protein selectively recruits P-TEFb as part of a super elongation complex (SEC) organized on a 
flexible AFF1 or AFF4 scaffold. To understand this specificity and determine if scaffold binding 
alters P-TEFb conformation, we determined the structure of a tripartite complex containing the 
recognition regions of P-TEFb and AFF4. AFF4 meanders over the surface of the P-TEFb cyclin T1 
(CycT1) subunit but makes no stable contacts with the CDK9 kinase subunit. Interface mutations 
reduced CycT1 binding and AFF4-dependent transcription. AFF4 is positioned to make unexpected 
direct contacts with HIV Tat, and Tat enhances P-TEFb affinity for AFF4. These studies define the 
mechanism of scaffold recognition by P-TEFb and reveal an unanticipated intersubunit pocket on 
the AFF4 SEC that potentially represents a target for therapeutic intervention against HIV/AIDS.
DOI: 10.7554/eLife.00327.001
Introduction
At many genes in humans—including the integrated HIV genome as well as loci that regulate develop-
ment and mediate responses to stress—RNA polymerase II initiates transcription but forms a stable 
paused complex after the synthesis of 30–50 nucleotides (Lin et al., 2011; Levine, 2012; Luo et al., 
2012a; Zhou et al., 2012). These paused polymerases are poised for rapid, synchronous efficient 
transcription. For these genes, escape of the paused polymerase from the promoter-proximal region 
and elongation of the mRNA are rate-limiting regulated processes. Promoter escape requires positive 
transcription elongation factor b (P-TEFb), a heterodimeric protein kinase composed of CDK9 and 
cyclin T1 (CycT1) subunits. P-TEFb triggers promoter escape by directly or indirectly stimulating phos-
phorylation of the RNA polymerase II C-terminal domain and the associated factors, NELF (negative 
elongation factor) and DSIF (DRB sensitivity inducing factor). Consequently, recruitment of active 
P-TEFb to the paused polymerase complex serves as an important checkpoint for gene expression 
(Levine, 2012; Luo et al., 2012b; Zhou et al., 2012).
P-TEFb cycles between inactive and active complexes (Zhou and Yik, 2006). Recent studies of 
gene fusions in myeloid leukemias (Lin et al., 2010; Yokoyama et al., 2010), as well as complexes 
recruited to the HIV promoter by the HIV Tat protein (He et al., 2010; Sobhian et al., 2010; Jager et al., 
2012), uncovered a family of Super Elongation Complexes (SECs) that bring together active P-TEFb 
and other transcription elongation factors. The SECs act at many normal human genes to stimulate 
mRNA elongation not only by triggering promoter escape but also by limiting proteolytic degradation 
of transcription elongation factors and increasing the processivity of RNAP II (He et al., 2010; Lin 
et al., 2010; Biswas et al., 2011; Liu et al., 2012). The SECs also couple to the PAF complex, which 
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stimulates efficient transcript elongation (He et al., 2011). In addition to P-TEFb, the SECs contain 
subunits in the AF4, ELL, and ENL/AF9 protein families. Despite the major roles of SECs in metazoan 
gene expression and human disease, little is known about the architecture of these complexes.
To define the interactions that mediate SEC assembly and to understand how HIV Tat recruits 
P-TEFb (Wei et al., 1998) in the context of these large protein complexes, we mapped contacts 
among SEC subunits (Figure 1A) (Chou et al., 2012). Here, we report the structural and functional 
analysis of P-TEFb in complex with the cognate binding site on the SEC scaffold protein, AFF4. These 
studies reveal that AFF4 recognizes P-TEFb by binding the CycT1 subunit on the side opposite from 
CDK9. AFF4 is positioned to make direct contacts with HIV-1 Tat. Tat increases the affinity of P-TEFb 
for AFF4 by over an order of magnitude in vitro and rescues P-TEFb binding of AFF4 interface mutants 
in vivo. These results suggest that the SEC scaffold is an unanticipated direct partner of HIV-1 Tat, and 
an intersubunit Tat-binding pocket in the AFF4-P-TEFb complex may afford an unexpected site to 
target with selective inhibitors of HIV transcription.
Results
The AF4 proteins, AFF1–4, form intrinsically disordered scaffolds that bind other transcription elonga-
tion factors not through folded domains but rather through dispersed short binding sites in the first 
750 amino acids (Chou et al., 2012; Leach et al., 2013) (Figure 1A). Residues 2–73 of AFF4, for example, 
are sufficient to bind P-TEFb through the CycT1 subunit, and a peptide encompassing AFF42–73 folds 
upon binding CycT1. Using this binding site, we determined the 2.9-Å-resolution crystal structure of 
AFF42–73-P-TEFb-AMPPNP (R/Rfree = 0.207/0.245; Figure 1, Figure 1—figure supplements 1 and 2, and 
Table 1).
In all three independent copies of the complex in the crystals, AFF4 residues Leu34-Ile66 are 
ordered, binding to the second cyclin domain of CycT1 opposite CDK9 (Figures 1B, 2). In one com-
plex, an isolated helix containing AFF4 residues 3–21 bridges symmetry-related CDK9 molecules 
in the crystals (Figure 1—figure supplement 2). We focus on the shared features of the three inde-
pendent complexes. Consistent with the coupling of folding to binding, AFF4 lacks intramolecular 
tertiary contacts as it snakes across the CycT1 surface. An extended segment in AFF4 tracks 
eLife digest The rates at which many genes are expressed as proteins are limited by the efficiency 
of a process called transcriptional elongation. This process takes place as the stretch of DNA that 
defines the gene is transcribed into an RNA molecule and it is catalyzed by an enzyme called RNA 
polymerase II. However, this enzyme can become trapped, and another enzyme called P-TEFb 
(positive transcription elongation factor b) is needed to release it. P-TEFb and other elongation 
factors therefore have an important role in gene expression.
The human immunodeficiency virus (HIV) is a retrovirus that hijacks the gene expression 
processes in human immune cells to replicate the RNA genome of the virus. To do this, the virus 
produces a protein called Tat that recruits P-TEFb as part of a multi-protein machine called the 
super elongation complex. This ensures that the process of transcriptional elongation, and hence 
the overall replication process, is highly efficient. There are gaps, however, in our knowledge of the 
architecture of the super elongation complex, which is known to be organized on a flexible scaffold. 
In turn, the molecular basis for the interaction between HIV-1 Tat and P-TEFb within the super 
elongation complex is not well understood.
Now Schulze-Gahmen et al. show that only one of the two subunits in P-TEFb—a cyclin known as 
CycT1—binds to the AFF4 scaffold protein in the super elongation complex. In addition to assisting 
with the expression of hundreds of human genes, super elongation complexes containing P-TEFb-AFF4 
are hijacked in various forms of cancer and viral infections, including HIV/AIDS. Schulze-Gahmen 
et al. show that AFF4 can directly contact HIV-1 Tat, which binds to the P-TEFb-AFF4 complex 
much more strongly than it binds to P-TEFb alone. This suggests that HIV-1 Tat evolved to work 
within the super elongation complex. Moreover, Schulze-Gahmen et al. reveal that HIV-1 Tat binds 
to a cleft between the P-TEFb enzyme and the AFF4 protein, which raises the possibility that this 
cleft could be used as a target for anti-HIV/AIDS drugs.
DOI: 10.7554/eLife.00327.002
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antiparallel to the H3′-H4′ loop in CycT1, and two short AFF4 helices fit into shallow grooves in CycT1 
between H3′ and H5′ and the surface formed by H2′ and H3′ (Figure 2A). Compared to the separated 
models, 1457 Å2 of AFF4 and 1251 Å2 of CycT1 accessible surface are buried in the complex. Twenty-
six of the 33 ordered residues in AFF4 contact CycT1, emphasizing the extensive recognition deter-
minants in the scaffold.
Many hydrophobic and aromatic residues in CycT1 mediate contacts with AFF4 (Figure 2B–C and 
Figure 2—figure supplement 1). A pocket between CycT1 Leu163-Val164-Arg165, Trp221, and 
Tyr224, for example, anchors AFF4 Phe35, which forms a classic edge-to-face interaction (Burley and 
Petsko, 1985) with the Tyr (Figure 2C). CycT1 Trp210 adjusts to create a site that buries AFF4 Pro38 
and allows a short antiparallel β-sheet to form between AFF4 Tyr39-Val41 and CycT1 Asn 209-Glu211 
(Figure 2—figure supplement 1A). CycT1 Trp207 shifts to form a hydrogen bond with the Gly57 
carbonyl in the loop between the two AFF4 helices, additional van der Waals contacts with the loop 
backbone and nonpolar contacts with AFF4 residues Leu56 and Tyr59 (Figure 2—figure supplement 1B). 
Eight intermolecular hydrogen bonds help establish the chemical complementarity between AFF4 and 
CycT1. Twenty-one of the 26 interacting residues in AFF4 are conserved in AFF1–3 (Figure 2—figure 
supplement 2).
In comparison to the structure of P-TEFb alone (CDK91–330/CycT11–259; PDB ID 3BLQ; Baumli et al., 
2008), the last 20 residues present in the CycT1 subunit undergo a major rearrangement upon AFF4 
binding (Figure 2D). AFF4 overlaps with the position of residues 243–259 in the superimposed P-TEFb 
cyclin subunit. To accommodate AFF4, helix H5′ straightens and residues 251–256 form a helical 
segment that packs against CycT1 helices H1 and H2’ and forms part of the AFF4 binding surface. In 
addition to burying hydrophobic residues in the first AFF4 helix, the adjustments in CycT1 helix 
H5′ mediate formation of a hydrogen-bonded ion pair between AFF4 Arg51 and CycT1 Glu246. 
CycT1 Trp256, the last residue ordered in the AFF4 complex, moves over 13 Å upon AFF4 binding.
To probe the basis for CycT1 binding, we measured the effects of interface mutations on the stability 
of the AFF4 complex in vitro. The AFF4 2–363 and 33–67 fragments bound to CycT1 with similar affini-
ties (Table 2), suggesting that the ordered AFF4 segment in the crystal structure captures the major 
CycT1 binding determinants. Mutations throughout the CycT1 interaction surface reduced AFF4 bind-
ing (Figure 3A and Table 3). The Trp210Ala and Trp207Ala substitutions in CycT1 had the largest 
effects, respectively, reducing AFF4 affinity by 21- and 58-fold. These results point to these CycT1 Trp 
residues as interaction hotspots and suggest that contacts all along the interface observed in the crystal 
structure mediate AFF4 recognition.
Figure 1. AFF4 binds CycT1 distal to CDK9. (A) Schematic model of the SEC. AFF4 is an intrinsically disordered 
scaffold that binds partners via 20–50 residue segments. (B) Ribbon diagram showing the strand–helix–helix 
arrangement of AFF4 (blue) bound to CycT1 (yellow) remote from CDK9 (teal). AFF4 adopts an extended conforma-
tion with no intramolecular tertiary contacts. AMPPNP (spheres) is bound to CDK9.
DOI: 10.7554/eLife.00327.003
The following figure supplements are available for figure 1:
Figure supplement 1. Electron density for AFF42–73. 
DOI: 10.7554/eLife.00327.004
Figure supplement 2. A crystal contact formed by AFF42–21. 
DOI: 10.7554/eLife.00327.005
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To examine the functional roles of the N-terminal 72 residues of AFF4, we measured the effects of 
tandem alanine mutations on the stimulation of expression of a luciferase reporter gene driven by the 
HIV-1 promoter in HeLa cells (He et al., 2011) (Figure 3B and Figure 3—figure supplement 1). 
Consistent with the structure, mutations of AFF4 residues that contact P-TEFb reduced Tat-independent 
transcriptional stimulation. Three of the most deleterious variations—alanine substitutions at Pro33/
Leu34, Phe35 (Ala36 was maintained), and Met55/Leu56—shorten hydrophobic side chains that are 
buried in the interface. Tandem alanine substitutions (Glu45/Asp46 and Gly57/Asn58) that remove 
side chains that cap and stabilize the AFF4 helices also reduced luciferase expression. In contrast, resi-
dues such as Glu61/Met62 and Ile71/Pro72, which are more tolerant of di-alanine substitutions, are 
more solvent exposed or flexible. Tandem alanine replacements in residues 3–32, which flank the 
ordered CycT1 contacts in the crystal structure, showed significant but generally smaller effects on 
AFF4 transcriptional stimulation activity (Figure 3B). These results implicate the P-TEFb binding site, 
as well as the flanking flexible sequences, in the function of the AFF4 N-terminal segment.
The HIV-1 Tat protein was shown nearly 15 years ago to bridge P-TEFb and the TAR RNA element 
near the 5′ end of nascent HIV transcripts to recruit the active CDK9 kinase to the HIV promoter (Wei 
et al., 1998). The discovery that Tat recruits P-TEFb as part of a larger SEC (He et al., 2010; Sobhian 
et al., 2010) raised the question of how Tat distinguishes the SEC from free P-TEFb, particularly since 
Table 1. X-ray data collection and refinement statistics for AFF4-P-TEFb-AMPPNP
Data collection AFF4-P-TEFb-AMPPNP
Space group P212121
Cell dimensions: a, b, c 100.691, 126.298, 195.626
Resolution (Å)* 50-2.94 (2.99–2.94)
Unique reflections* 54,189 (2664)
Rsym (%)* 9.3 (>100)
I/σ(I)* 23.2 (1.3)
Completeness (%)* 100.0 (100.0)
Redundancy* 8.1 (7.5)
Temperature (K) 100
Mosaicity (°) 0.45–0.6
Refinement
Resolution (Å) 48.7-2.94
No. reflections 53,775
Rwork/Rfree 0.207/0.245
No. atoms/B-factors (Å2)
  CDK9, molecule 1, 2, 3 2558 (111.9), 2533 (116.3), 2558 (121.6)
  Cyclin T1, molecule 1, 2, 3 2003 (121.3), 2024 (123.1), 2001 (118.5)
  AFF4, molecule 1, 2, 3 248 (156.3), 421 (161.1), 243 (160.3)
  Water 19 (90.1)
Root mean square deviations
  Bond lengths (Å) 0.004
  Bond angles (°) 0.666
Ramachandran plot†
  Favored (%) 94.7
  Allowed (%) 4.48
  Disallowed (%) 0.78
Protein Data Bank ID 4IMY
*Values in parentheses are for the highest resolution shell.
†Values from MOLPROBITY.
DOI: 10.7554/eLife.00327.006
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Tat binds P-TEFb in isolation. Moreover, Tat shows specificity for SECs containing AFF4 and AFF1 (He 
et al., 2010; Sobhian et al., 2010). What accounts for this specificity? The AFF4-P-TEFb crystal structure 
provides a simple and unsuspected explanation—Tat binds in a position to make direct contacts with the 
scaffold (Figure 4A). Superposition of the CycT1 subunits of the structures of Tat-P-TEFb (Tahirov et al., 
2010) and AFF4-P-TEFb shows that Tat is positioned to pack against helix 2 of AFF4. Tat Met1, Lys28 
(which is reversibly acetylated in vivo; Kiernan et al., 1999; Ott et al., 2011) and Phe32, in particular, are 
predicted to interact with AFF4 Glu61, Met62, Phe65, and Ile66. The disordered C-terminus of the AFF4 
peptide also neighbors Glu2 and His13-Gly15 of Tat. These seven residues of Tat are crucial for transcrip-
tional activation, even though they are exposed to solvent in the Tat-P-TEFb complex (D’Orso et al., 2012).
The juxtaposition of AFF4 and Tat on the P-TEFb surface predicts that the scaffold enhances Tat 
binding. Direct measurements of Tat affinity are problematic, however, because Tat is unstable in vitro 
in the absence of partners and difficult to maintain in an active form. To overcome this problem, we took 
advantage of a thermodynamic cycle that illustrates that AFF4 and Tat mutually influence the P-TEFb 
affinity of each other by the same amount (Figure 4—figure supplement 1). In quantitative in vitro 
Figure 2. Basis for AFF4 scaffold recognition by P-TEFb. (A) AFF4 residues 34–66 (blue spheres) fill grooves on 
CycT1 (yellow surface). (B) Chemical complementarity mediates AFF4 binding. Exposed hydrophobic residues of 
CycT1 (yellow surface) are buried in the AFF4 complex. Hydrogen bonds (black dotted lines) also mediate binding. 
(C) AFF4 Phe35 is buried in a hydrophobic pocket formed by aromatic and nonpolar residues on the surface of CycT1. 
(D) The C-terminus of the CycT1 cyclin domain (gray in the ellipse) adjusts to make contacts with AFF4 (blue).
DOI: 10.7554/eLife.00327.007
The following figure supplements are available for figure 2:
Figure supplement 1. Example interactions between AFF4 and P-TEFb. 
DOI: 10.7554/eLife.00327.008
Figure supplement 2. Conserved AFF4 sequences mediate P-TEFb recognition. 
DOI: 10.7554/eLife.00327.009
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assays (Figure 4B and Table 2), the purified AFF42–73 peptide bound Tat-P-TEFb (Kd = 0.85 ± 0.15 nM) ∼11 
times more tightly than P-TEFb (Kd = 10 ± 1 nM). The AFF42–363 segment also bound Tat-P-TEFb (Kd = 
0.6 ± 0.1 nM) ∼11 times more tightly than P-TEFb (Kd = 7 ± 1 nM). These results support the model of 
direct Tat interactions with AFF4 and suggest that the AFF42–73 peptide includes the principal residues 
that contact Tat (Figure 4 and Figure 4—figure supplement 1).
To test the importance of the AFF4 interactions for P-TEFb and Tat recognition in vivo, we meas-
ured the effects of mutations in AFF4 on the binding of SEC subunits and Tat in HeLa cells. Cells were 
transfected with wild-type or mutant AFF4 containing a C-terminal 3× FLAG tag, and immunoprecipi-
tations using an anti-FLAG antibody were probed for the presence of associated factors. Alanine 
substitutions in P-TEFb contacts such as AFF4 Phe35, Tyr59/Asp60, and Lys63/Asp64 reduced binding 
of P-TEFb but not the ELL2, AF9, or ENL subunits of the SEC (Figure 4C). These defects were rescued 
by overexpressing a stably integrated gene for Tat, which strengthened the AFF4-P-TEFb associa-
tion. In contrast, tandem alanine substitutions for AFF4 Glu61/Met62, which are more exposed in the 
P-TEFb interface and predicted to contact Tat, caused a small reduction (∼30%) in the binding of 
P-TEFb that was not rescued by overexpressing Tat (Figure 4C). The specificity of these mutational 
effects supports the model that Tat interacts directly with AFF4.
In keeping with the tenuous contacts of the AFF43–21 helix with CDK9, AFF42–73 (Kd = 10 ± 1 nM) 
binds only 3.6 times more tightly than AFF4 32–67 (Kd = 36 ± 4 nM) to P-TEFb (Table 2). In addition, the 
CDK9 kinase subunit structure is little changed upon AFF4 binding to P-TEFb (CDK915–360 RMSD = 0.54 Å 
vs 1BLQ). In vivo, the Glu13Ala/Arg14Ala AFF4 mutant in the heart of the CDK9 interface in the crystals 
is associated with a <25% decrease in transcription stimulation (Figure 3B) and little change in P-TEFb 
binding (Figure 4C). To measure if recruitment of P-TEFb to the SEC scaffold regulates the kinase, 
we assayed the effects of AFF4 on the in vitro phosphorylation of an RNA polymerase II CTD substrate 
by purified P-TEFb and Tat-P-TEFb (Bitoun et al., 2007). AFF42–73 inhibited CTD phosphorylation by 
approximately twofold in a purified system (Figure 5 and Figure 5—figure supplements 1 and 2). By 
comparison, Tat stimulated P-TEFb by sevenfold, and addition of AFF2-73 did not further stimulate the 
kinase activity of the Tat-P-TEFb complex. Taken together, these results point away from CDK9 as the 
primary physiological partner of AFF43–21 and suggest that AFF4 functions as a SEC scaffold but not an 
allosteric activator of CDK9.
Discussion
The AFF4-P-TEFb crystal structure reveals that a high density of contacts in residues 34–66 of the AFF4 
scaffold mediates binding to the CycT1 subunit of P-TEFb. These contacts are largely conserved in AF4 
family members and can be perturbed physically and functionally by mutations (Figure 3 and Figure 2—
figure supplement 2). Consistent with these results, tandem alanine substitutions of Pro33/Leu34, 
Val41/Thr42, Arg51/Ile52, and Met55/Leu56 in the CycT1 binding site (but not Arg3/Glu4 or Glu25/
Asp26 in the preceding segment) also reduce P-TEFb binding in vivo (Chou et al., 2012). The impacts of 
alanine substitutions on transcriptional stimulation by AFF4 (Figure 3B) show that residues in the P-TEFb 
interface, as well as helix stabilizing residues, play crucial roles. The additional sensitivity of transcrip-
tional stimulation to alanine substitutions of disordered residues flanking the CycT1 binding site suggests 
that the flexibility and potential interactions with other ligands are important for function.
Table 2. Binding affinities of AFF4 segments
Direct binding Competition assay
AFF432–67 AFF432–67 AFF42–73 AFF42–363
CycT1 104 ± 17 nM 102 ± 10 nM 130 ± 18 nM 115 ± 15 nM
P-TEFb 36 ± 6 nM 36 ± 4 nM 10 ± 1 nM 7 ± 1 nM
Tat-P-TEFb 8.8 ± 0.8 nM 4.5 ± 0.6 nM 0.85 ± 0.15 nM 0.6 ± 0.1 nM
Dissociation constants measured by direct binding of fluorescein-labeled AFF432–67 and by competition with 
unlabeled AFF4 segments. The increased affinity of AFF4 for P-TEFb compared to CycT1 may be due to structural 
changes in the cyclin subunit or additional interactions with the CDK9 kinase subunit. The similar affinities of 
AFF42–73 and AFF42–363 for all the cyclin-containing species suggest that AFF42–73 encompasses the binding sites for 
P-TEFb and Tat-P-TEFb.
DOI: 10.7554/eLife.00327.010
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HIV-1 Tat binds adjacent to AFF4, increases the affinity of AFF4 for P-TEFb by over an order of 
magnitude, and rescues P-TEFb binding to AFF4 interface mutants in vivo. The AFF4 Glu61/Met62 
double alanine substitution in the proposed Tat interface blocks this rescue. These results suggest that 
Figure 3. AFF4 interface mediates P-TEFb recognition. (A) Mutations of CycT1 contact residues reduce AFF4 
affinity. Fluorescence polarization of fluorescein-labeled AFF432–67 (5 nM) is plotted as a function of the concentra-
tion of the indicated CycT1 variant. (B) Transcriptional effects of AFF4 tandem Ala mutants. Stimulation of Tat-
independent transcription from the HIV LTR was measured in extracts of cells cotransfected with a luciferase 
reporter construct and an expression vector for the indicated di-Ala AFF4 variant. Activity was normalized to the 
level of AFF4 expression. Values represent the mean of three independent assays. Tandem alanine substitutions 
cover the first 72 residues of AFF4. Horizontal lines correspond to the mean stimulation of di-Ala substitutions in 
residues 3–32 (left; 113.9 ± 5.1) and 33–66 (right; 73.6 ± 4.9).
DOI: 10.7554/eLife.00327.011
The following figure supplements are available for figure 3:
Figure supplement 1. Expression levels of AFF4 variants. 
DOI: 10.7554/eLife.00327.012
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direct contacts between Tat and the AFF4 scaf-
fold in complex with P-TEFb mediate the selec-
tive recruitment of the SEC to the HIV promoter. 
The functional AFF4-Tat interface, including the 
acetylated Lys28 in Tat as a potential regulator of 
affinity (Kiernan et al., 1999), supports the idea 
that Tat evolved to function within the SEC. In the 
crystal structure of the (low-affinity) Tat-P-TEFb 
subcomplex (Tahirov et al., 2010), Tat binds to 
a relatively open groove. In the context of the 
AFF4-P-TEFb structure, however, AFF4 creates 
an unanticipated pocket for Tat (Figure 4D). This 
pocket may ultimately provide a suitable therapeu-
tic target for the development of small-molecule 
inhibitors of Tat binding that selectively block 
HIV transcription.
Materials and methods
Expression of P-TEFb, P-TEFb-Tat, and AFF4
CDK9 (1–330) and cyclin T1 (1–264) were cloned into a modified pFastBac Dual donor plasmid, and 
HIV-1 Tat (1–86) was cloned into the pFastBac1 donor plasmid using the Bac-To-Bac system from Life 
Technologies (Carlsbad, CA). CDK9 was cloned with a Tobacco Etch Virus (TEV) protease cleavable 
N-terminal His-tag while CycT1 and Tat remained un-tagged. Each virus genome was transfected into 
Sf9 cells to generate the baculovirus according to manufacturer’s protocol. Each baculovirus was 
amplified (2×), plaque purified, and amplified (3×) to obtain a stock with 108 plaque forming units 
(PFU)/ml. Test infections were screened for expression levels of the target proteins by Western blot 
analysis, and the highest expressing virus stock was used.
For large-scale production of P-TEFb, 4 l of High5 cells at 1 × 106 cells/ml in ESF921 medium 
(Expression Systems, Reno, NV) were infected with 20 ml of virus stock per liter of culture. The 
flasks were incubated for 52 hr at 27°C on a rotary shaker. Cells were harvested by centrifugation 
for 30 min at 350xg in a Beckmann JLA-8.1 rotor, washed quickly in 50 mM Tris pH 7.5, 150 mM 
NaCl, and centrifuged at 350×g for 10 min. The supernatant was removed, and the cell pellets 
were frozen in liquid nitrogen. For large-scale production of P-TEFb-Tat, insect cells were coinfected 
with 20 ml each of CDK9, CycT1, and Tat virus stocks. The remaining steps were the same as for 
production of P-TEFb.
AFF42–73 was cloned into a modified pET28 plasmid. The recombinant protein includes a N-terminal 
TEV-protease-cleavable His-tag. The plasmid was transformed into Rosetta(DE3)pLysS. 3 l of trans-
formed Escherichia coli were grown at 37°C to OD600 = 0.6, and expression was induced with 0.3 mM 
IPTG at 18°C for 16 hr. Cells were harvested, and pellets were frozen in liquid nitrogen.
Purification of the AFF4-P-TEFb complex
Pellets from 4 l infected High5 cells were resuspended in 75 ml lysis buffer (20 mM Na-HEPES pH 7.4, 
10 mM NaCl, 1 mM DTT) with 1 × Roche Complete Protease Inhibitor and 0.5 mM AEBSF. Cells were 
lysed with a Dounce homogenizer. The lysate was brought up to 0.2 M NaCl by adding 3.0 ml 5 M 
NaCl, incubated on ice for 10 min, and centrifuged at 5800xg in a SS34 rotor. The supernatant was 
saved, and the pellet extracted again with 30 ml lysis buffer in the homogenizer. The supernatants of 
the two centrifugations were combined, cleared by centrifugation at 210,000×g in an ultracentrifuge, 
and filtered through a 0.8-μm syringe filter. The cleared lysate was loaded onto a 5 ml His-Trap HP column 
(GE Healthcare, Piscataway, NJ) equilibrated in buffer A (20 mM Na-HEPES pH 7.4, 0.3 M NaCl, 10% 
glycerol, 1 mM DTT, 20 mM imidazole). After washing for 10 column volumes with buffer A + 1 M NaCl, 
followed by 10 column volumes of buffer A, P-TEFb was eluted with a gradient from 0% A to 100% B 
(20 mM Na-HEPES pH 7.4, 0.3 M NaCl, 10% glycerol, 0.5 M imidazole, 1 mM DTT). The eluted P-TEFb 
was dialyzed for 3 hr against 2 L buffer A. TEV-protease was added to the protein at a 1:25 (wt/wt) 
ratio, and the digest was incubated for 1 hr at room temperature and 4°C overnight. The digest was 
loaded on a His-Trap HP column, and P-TEFb lacking the His tag eluted in the flow-through of the 
Table 3. Dissociation constants of AFF432–67 for 
Cyclin T1 mutants
CycT1 variant Kd (nM)
Wild-type 104 ± 17
Y175A 228 ± 18
E211A 356 ± 29
D169A 438 ± 41
F176A 645 ± 58
R165A 1592 ± 171
W210A 2190 ± 246
W207A 6050 ± 871
DOI: 10.7554/eLife.00327.013
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column, while undigested protein and TEV-protease eluted later in the imidazole gradient. The yield 
was ∼0.8 mg P-TEFb/L High5 cell culture.
The Tat-P-TEFb complex was purified in a similar way. The cell lysate was purified over a 5 ml His-
Trap HP column, dialyzed, and digested with TEV protease as described above. The digested complex 
was diluted with 1.1 volumes of 20 mM Na-HEPES pH 7.3, 1 mM DTT, 1% β-octyl-glucoside to a final 
concentration of 0.14 M NaCl, and 0.5% β-octyl-glucoside and applied to a Source S anion exchange 
column equilibrated in 20 mM Na-HEPES pH 7.3, 10% glycerol, and 1 mM DTT. The column was devel-
oped with a linear gradient to 20 mM Na-HEPES pH 7.3, 0.75 M NaCl, 10% glycerol, and 1 mM DTT. 
P-TEFb-Tat eluted as single peak at about 0.25 M NaCl.
To purify AFF42–73, 30 g of E. coli cell pellet was resuspended in 125 ml lysis buffer (25 mM Tris/HCl 
pH 7.5, 0.2 M NaCl, and 1 mM DTT). Lysozyme was added to 0.1 mg/ml final concentration and incu-
bated for 30 min. After adding Roche Complete Protease Inhibitor without EDTA, 0.5 mM AEBSF, and 
Figure 4. AFF4 binds in position to make direct contacts with HIV-1 Tat. (A) Superposition of the AFF4-P-TEFb 
complex and the Tat-P-TEFb complex using the cyclin subunit (yellow) shows the close proximity of AFF4 (blue) and 
Tat (red). Tat Lys28 (pink), where acetylation stimulates function, as well as other residues essential for Tat transcriptional 
activation (D’Orso et al., 2012) that are exposed to solvent in the Tat-P-TEFb complex (bright red) are positioned 
adjacent to AFF4. (B) Tat enhances AFF4 binding in vitro. Fluorescence polarization of fluorescein-labeled AFF432–67 
(5 nM) is plotted as a function of the concentration of CycT1 (blue circles), P-TEFb (red squares), and Tat-P-TEFb 
(green triangles). (C) Alanine substitutions in the P-TEFb binding site of AFF4 reduce CycT1 binding but not associations 
of other SEC subunits in HeLa cells. Western blots show associations of each indicated factor with different FLAG-
tagged AFF4 variants (top). Lysates were immunoprecipitated with an anti-FLAG antibody. Expression of Tat (right) 
rescues defects in CycT1 binding, except for the E61/M62 double alanine mutant. This mutant in the predicted 
AFF4-Tat interface shows equal small defects in P-TEFb binding in the absence (left) and presence (right) of Tat. 
(D) AFF4 (blue) and CycT1 (yellow) create an intersubunit pocket where Tat (red) can bind with minor structural 
adjustments. The program DoGSiteScorer (Volkamer et al., 2012) assigns this cleft a high druggability score (0.83 out 
of 0–1.0) and shows that it contains the most nonpolar surface of any pocket in the AFF4-P-TEFb structure.
DOI: 10.7554/eLife.00327.014
The following figure supplements are available for figure 4:
Figure supplement 1. Thermodynamic cycle for AFF4 and Tat binding to P-TEFb. 
DOI: 10.7554/eLife.00327.015
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DNaseI (5 units/ml), the cells were lysed by sonication. The lysate was centrifuged for 1 hr at 17,000 rpm 
in a SS34 rotor. The supernatant was filtered through a 0.8-μm syringe filter and applied to a 5 ml His-Trap 
column. The protein was purified as described for P-TEFb.
The separately purified P-TEFb and AFF42–73 were combined at a 1:1.4 (mol/mol) ratio, concen-
trated to 0.6 ml, and injected onto an analytical Superdex S200 gel exclusion column equilibrated with 
25 mM Na-HEPES pH 7.4, 0.2 M NaCl, and 1 mM DTT. The center fractions of the eluted three-protein 
peak were used for crystallization.
Crystallization and structure determination
The purified AFF4-P-TEFb complex was concentrated to 10 mg/ml using Millipore Ultrafree centrifugal 
devices. Crystals were grown from 1.0 µl protein combined with 0.5 µl silver bullet condition 30 
(Hampton Research, Aliso Viejo, CA; 0.33% wt/vol Gly-Phe, 0.33% wt/vol Gly-Tyr, and 0.33% wt/vol 
Leu-Gly-Gly in 20 mM Na-HEPES pH 6.8) and 0.5 µl reservoir solution equilibrated against 16–18% 
PEG 3350, 0.1 M Na-HEPES pH 7.0. After equilibrating for 24 hr, diluted microseeds from previous 
Figure 5. Kinase activity of P-TEFb and P-TEFb-Tat complexes with AFF4. (A) Autoradiogram showing phosphorylation of GST-CTD (500 ng) by P-TEFb 
and P-TEFb-Tat with and without excess (0.28 μM) AFF42-73 in the presence of low (50 μM) ATP. (B) Phosphorylation of 500 ng GST-CTD by P-TEFb and 
P-TEFb-Tat with and without excess (0.28 μM) AFF42–73 in the presence of saturating (500 μM) ATP. AFF4 reduces the activity of P-TEFb twofold and has 
little influence on the kinase activity of Tat-P-TEFb. Tat-P-TEFb is, however, sevenfold to tenfold more active than P-TEFb. Lane 3 in panels (A and B) is a 
control without GST-CTD. (C) Quantitation of the radioactive GST-CTD in (A and B).
DOI: 10.7554/eLife.00327.016
The following figure supplements are available for figure 5:
Figure supplement 1. SDS polyacrylamide gel of P-TEFb and P-TEFb-Tat at the same ratio as they were used in the kinase assay. 
DOI: 10.7554/eLife.00327.017
Figure supplement 2. Western blots of kinase reaction products from panel B. Phosphorylated CTD was detected with anti-phoshoSer2 and 
anti-phoshoSer5 antibodies. 
DOI: 10.7554/eLife.00327.018
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crystallization experiments were added with a hair. Seeding produced large single crystals (0.3 × 0.2 × 
0.2 mm) with and without 1 mM AMPPNP, 5 mM MgCl2. The presence of all three proteins in the crys-
tals was confirmed by gel electrophoresis and mass spectrometry of dissolved crystals.
Crystals were soaked in cryoprotectant (25% PEG 3350, 0.1 M Na-HEPES pH 7.0, 10% glycerol, 1:4 
silver bullet 30) and flash frozen in liquid nitrogen. X-ray data were collected at Beamline 8.3.1 at the 
Advanced Light Source at the Lawrence Berkeley National Laboratory (MacDowell et al., 2004). The 
best data were collected from a crystal that was grown in the presence of 1 mM AMPPNP and 5 mM 
MgCl2. The reflections were processed using HKL2000 (Otwinowski and Minor, 1997) (Table 1).
The structure was determined by molecular replacement with PHENIX (Adams et al., 2010) using 
P-TEFb from the P-TEFb-Tat complex (PDB ID 3MI9) as the search model. The asymmetric unit 
contains three complexes. Initial refinement using PHENIX was performed with model restraints, as 
well as noncrystallographic symmetry restraints. Model restraints were removed in later stages of 
refinement. AFF4 was built manually and the model was adjusted using Coot (Emsley and Cowtan, 
2004). The model was refined using gradient minimization with weight optimization and maximum-
likelihood targets, TLS refinement, and individual atomic B-factor refinement. The model was checked 
against composite omit maps. Density was missing for residues 1–7 and 88–95 in CDK9 mol1 and mol3, 
and residues 1–7 and 89–97 in CDK9 mol2. Density also was absent for residues 1–7 and 253–264 in 
CycT1 mol1, residues 1–7 and 257–264 in CycT1 mol2 and mol3, and residues 2–33 and 67–73 in 
AFF4, mol1 and mol3. For AFF4 in molecule 2 residues 2, 22–33, and 67–73 are missing.
The register of the AFF4 sequence in the electron density was confirmed by locating the Se atoms 
in crystals grown with SeMet-labeled AFF4. AFF42−73 was labeled with SeMet (Van Duyne et al., 1993) 
and purified as described above. Optimized crystallization conditions were seeded with unlabeled 
microcrystals. Anomalous differences were calculated from data collected at 12,657 eV, the peak of 
Se fluorescence measured from the crystal.
Structure analysis
Buried surface areas were calculated with PISA (Krissinel and Henrick, 2007). Surface pockets were 
identified with the program DoGSiteScorer (Volkamer et al., 2012). Figures of molecular structures 
were prepared with PyMOL Version 1.5 (Schroedinger LLC, New York, NY).
AFF4 affinity for CycT1
Protein binding was measured using fluorescence anisotropy of a 36-residue segment of AFF4 (residues 
32–67) encompassing the protein–protein contacts in the crystal structure. The AFF4 peptide was syn-
thesized at the University of Utah DNA/Peptide Facility using the following sequence: C-FAM-GABA-
SPLFAEPYKVTSKEDKLSSRIQSMLGNYDEMKDFIG-amide where FAM indicates 5-carboxyfluoroscein 
and GABA indicates a γ-amino-butyric acid spacer. Varying amounts of purified CycT1, P-TEFb, and 
Tat-P-TEFb were incubated for 30 min with 5 nM labeled peptide at room temperature in the dark in 
25 mM HEPES pH 7.5, 100 mM NaCl, 10% glycerol, 0.1% NP40, and 0.5 mM Tris(2-carboxyethyl)phosphine 
(TCEP). Competition titration experiments of unlabeled peptides were performed using 75 nM CycT1, 
45 nM P-TEFb, and 6 nM Tat-P-TEFb in 25 mM HEPES pH 7.5, 100 mM NaCl, 10% glycerol, 0.1% 
NP40, 0.5 mM TCEP, and 5 nM fluorescent peptide. Fluorescence anisotropy was measured using a 
Victor 3V (Perkin Elmer) multi-label plate reader. Data points represent the average of six independent 
measurements. Binding curves were fit to the single-site binding equation using Prism version 5.0c 
(Graphpad Software).
AFF4 stimulation of Tat-independent transcription
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS at 37°C 
in a humidified atmosphere with 5% CO2. Cells were seeded at 5 × 105 cells/ml in TC-treated 96-well 
plates one day prior to plasmid transfection using the 25-kDa linear polyethyleneimine reagent (Sigma-
Aldrich, St. Louis, MO). Cells were cotransfected with 100 ng of an HIV-LTR firefly luciferase reporter 
construct (He et al., 2010) and 350 ng of pCDNA3.1 containing AFF4 variants with a C-terminal 
3× FLAG tag. Following stimulation for 48 hr with the indicated ligands, the cells were lysed in passive 
lysis buffer (Promega, Fitchburg, WI) for 5 min at 25°C. The cell lysates were incubated with firefly 
luciferase substrate, and luminescence was measured on a SpectraMax L microplate reader (Molecular 
Devices, Sunnyvale, CA). The relative luminescence was normalized to the concentration of AFF4 in the 
cell determined by Western blotting using an anti-FLAG primary antibody.
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Co-immunoprecipitation and detection of proteins bound to AFF4
HeLa cells were seeded in 10-cm TC-treated plates at 2.2 × 105 cells/ml, Incubated for 24 hr and trans-
fected with pCDNA3.1 (1 μg) encoding an AFF4 variant with a C-terminal 3× FLAG tag. After incubating 
for 2 days, cells were collected in PBS, washed, and resuspended in hypotonic buffer (20 mM Tris-HCl 
pH 7.4, 10 mM NaCl, and 3 mM MgCl2). After 15 min on ice, 0.4% Triton X-100 was added, and the 
cell suspension was mixed and centrifuged at 3000×g for 10 min. The pellet was resuspended in 
nuclear extraction buffer (100 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% 
glycerol, 0.7% Tween 20, and protease inhibitors [AEBSF, leupeptin and E64]) for 30 min on ice 
followed by centrifugation at 14,000×g for 30 min to yield nuclear extract. Anti-FLAG agarose beads 
(Sigma-Aldrich) were incubated in the nuclear extract at 4°C for 2 hr and washed with nuclear extraction 
buffer. The beads were eluted with 0.1 M glycine-HCl pH 3.5, and the neutralized eluate was analyzed 
by Western blotting with the indicated antibodies.
P-TEFb kinase assays
Kinase assays were performed in LoBind tubes (Eppendorf) in 20 μl reactions containing 50 mM HEPES 
pH 7.3, 50 mM NaCl, 1 mM DTT, 10 mM MgCl2, and 0.05 mM or 0.5 mM ATP. For assays with 0.05 mM 
ATP, 0.15 μCi [32P]-γ-ATP was used, and for reactions with 0.5 mM ATP, 1.5 μCi [32P]-γ-ATP was used. 
Reactions in conventional tubes gave distinct less reproducible results. Purified recombinant P-TEFb or 
P-TEFb-Tat was pre-incubated with 500 ng purified recombinant GST-CTD (52 C-terminal domain repeats 
from human RNA polymerase) in the absence or presence of 0.3 µM purified AFF42–73 for 15 min at 20°C. 
After addition of ATP, the kinase reactions were stopped at different times by addition of 5 μl of 5× SDS 
sample buffer. The samples were analyzed by SDS-polyacrylamide gel electrophoresis, followed by 
measurement of the radioactive protein bands on a Typhoon phosphorimager (GE Healthcare).
For Western blots of kinase reactions performed with non-radioactive ATP, 0.2 µg of GST-CTD from 
each reaction was loaded per lane of a 4–20% SDS-PAGE gel, transferred onto a PVDF membrane 
(Immobilon-FL; Millipore, Billerica, MA) and processed by standard Western Blot procedures. The 
primary antibodies were ab5095 (αpS2; Abcam) and ab5131 (αpS5; Abcam) at 1:1000 dilution for 
both. The secondary antibody was a fluorescently labeled goat anti-rabbit antibody (Odyssey; LI-COR 
Biosciences, Lincoln, NE) at 1:20,000 dilution.
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